Stockscreener 앱 받기
7.71
0.52%
-0.04
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha
Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $50.88 - Defense World
Bank of America Corp DE Buys 7,207 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
11,027 Shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Bought by Two Sigma Advisers LP - Defense World
(CRBP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Nuveen Asset Management LLC Has $341,000 Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Dermatomyositis Market Predicted to See Upsurge Through 2034, - openPR.com
Two Sigma Investments LP Purchases 91,205 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Deutsche Bank AG - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Acquires 11,400 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
BNP Paribas Financial Markets Makes New Investment in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
(CRBP) Proactive Strategies - news.stocktradersdaily.com
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Corbus Pharmaceuticals CEO Set to Reveal Latest Corporate Strategy at Major Jefferies Healthcare Conference - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives $50.88 Average Target Price from Analysts - Defense World
Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating - marketscreener.com
Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating - marketscreener.com
Cannabis Stock Movers For May 20, 2025 - Benzinga
Corbus Pharmaceuticals appoints new board chair - Investing.com Australia
Corbus Pharmaceuticals appoints new board chair By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals Appoints New Chair of the Board - TipRanks
Corbus Pharmaceuticals (CRBP) Names New Chair to Board of Direct - GuruFocus
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - GlobeNewswire
Corbus Pharmaceuticals Appoints Industry Leader as Chair with 3 Major Clinical Readouts Coming - Stock Titan
(CRBP) Investment Analysis - news.stocktradersdaily.com
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment? - sharewise
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Barclays PLC - Defense World
Wells Fargo & Company MN Has $76,000 Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Tower Research Capital LLC TRC - Defense World
Oppenheimer Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $56.00 - Defense World
B. Riley Expects Reduced Earnings for Corbus Pharmaceuticals - Defense World
HC Wainwright Cuts Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $40.00 - Defense World
Wedbush Expects Weaker Earnings for Corbus Pharmaceuticals - Defense World
HC Wainwright Issues Negative Forecast for CRBP Earnings - Defense World
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Royal Bank of Canada Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - Defense World
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewswire
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? - Zacks Investment Research
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
CRBP: RBC Capital Lowers Price Target, Maintains Outperform Rati - GuruFocus
Oppenheimer Lowers Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals (CRBP) Target Price Reduced by Analyst | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals (CRBP) Target Price Adjusted by RBC Capital | CRBP Stock News - GuruFocus
CRBP: HC Wainwright & Co. Lowers Price Target for Corbus Pharmaceuticals | CRBP Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Corbus Pharmaceuticals (CRBP) | CRBP Stock News - GuruFocus
RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk - marketscreener.com
Corbus Pharmaceuticals (CRBP) Sees Price Target Reduction | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals: Q1 Earnings Snapshot - CTPost
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Advances Clinical Pipeline Amid Q1 Loss - TipRanks
0.68%
0.50%
자본화:
|
볼륨(24시간):